The COVID-19 Pandemic is a Global Public Health Priority


1. Americas

2. Europe

3. South-East Asia

WHO August 2020

Global confirmed cases of COVID-19 have surpassed
23 million

WHO August 2020

An estimated 50-80% of COVID-19 cases are asymptomatic, and thus not likely to be diagnosed

Global Data Healthcare

In the USA, confirmed COVID-19 cases have reached
5 million

CDC August 2020

WHO August 2020

“Non-invasive SARS-CoV-2 antibody testing is urgently needed to estimate the incidence and prevalence of the SARS-CoV-2 infection.”

– Johns Hopkins Bloomberg School of Public Health

(Ref: Source: Randad PR, Pisanic N, Kruczynski K, et al. COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva. Preprint. medRxiv. 2020;2020.05.24.20112300. Published 2020 May 26. doi:10.1101/2020.05.24.20112300)

  • Non-invasive
  • Real-time results
  • Quantifies levels of immunity and/or exposure (rather than just positive or negative result)
  • Ability to be printed at scale, at a low cost

GBS Inc. has Collaborated with Harvard University to Develop a Real-time SARS-CoV-2 Antibody Biosensor

The Wyss Institute for Biologically Inspired Engineering at Harvard University is integrating our world-first Biosensor Platform technology with a specialised nanomaterial coating.

This gel-like coating allows the detection of IgM and/or igG antibodies which indicates a person’s current or previous exposure to the SARS-CoV-2 virus, and thus, a potential infection with COVID-19.

Further development could result in a chewing-gum sized diagnostic ‘strip’ to be used as a diagnostic tool for COVID-19 testing at point of care.

Sign Up

Register for email alerts for the latest on the Biosensor Platform and GBS Inc.

  • This field is for validation purposes and should be left unchanged.